The non-obese diabetic-severe combined immunodeficiency (NOD-SCID) mouse is a convenient host for human hematopoietic tissues and cells. Human fetal bone fragments engrafted subcutaneously in NOD-SCID mice sustain human hematopoiesis for several months. MS5 murine bone marrow stromal cells were transfected by electroporation with a plasmid containing the human interleukin-3 gene. As expected, stably transfected hu-IL3-MS5 cells supported human hematopoiesis in vitro more efficiently than MS5 cells. hu-IL3-MS5 cells were then injected intravenously into hu-NOD-SCID mice to test their ability to home to the mouse and/or human bone marrow, and to evaluate the role of hu-IL3 secretion on human hematopoiesis in vivo. hu-IL3 was detected in the mouse serum for up to an observation time of 8 weeks. hu-IL3-MS5 cells engrafted the bone marrow, spleen, liver and lungs of the mice but also the human bone graft. The presence of hu-IL3-MS5 cells in the human bone significantly stimulated local human hematopoiesis. This setting could be used to model the bone marrow homing of intravenously injected stromal cells or stromal cell precursors. The same experimental principle could also be applied in a therapeutic perspective to malignant human bone marrow hematopoiesis.
Introduction
The production of mature blood cells from hematopoietic stem cells (HSC) is controlled by the microenvironment constituted by bone marrow stromal cells. Stroma comprises various types of cells: fibroblasts, adipocytes, endothelial cells and macrophages. These cells interact with hematopoietic cells by direct contact mediated by adhesion molecules, and by soluble growth factors. Stromal functions can be altered in hematological pathologies. In malignant diseases, stromal dysfunctions can result from modifications of adhesion molecule expression or growth factor production by stromal cells. 1 Recent data indicate that infection of bone marrow stromal cells by human immunodeficiency virus in vitro lessens their ability to support hematopoiesis. 2, 3 Stromal cells are now proposed as targets for gene therapy of some hematological disorders. 4 For example, transgenic stromal cells could directly deliver hematopoietic growth factors in the bone marrow over long periods of time, since some of them at least are thought to be long-lived, which differs from most hematopoietic cells. In the case of accidental radiation-induced bone marrow aplasia, the local production of growth factors could provide an alternative to systemic administration of growth factors which is often complicated by severe side-effects, with high doses being injected to the patients. The aim of the present study was to evaluate the ability of bone marrow stromal cells engineered to produce a human growth factor and injected in vivo to influence human hematopoiesis in a mouse/human chimera model. Human fetal bone fragments engrafted in the severe combined immunodeficiency (SCID) mouse support human hematopoiesis in its natural microenvironment for several months. 5, 6 The maintenance of some cell lineages in these conditions requires the infusion of growth factors; for example human erythropoietin is necessary for red cell production to be sustained in the human bone graft. 6 More generally, the effect of infused human hematopoietic growth factors on human hematopoiesis in vivo can be directly evaluated in SCID mouseimplanted human fetal bone. 7 We used herein non-obese diabetic-severe combined immunodeficiency (NOD-SCID) mice, which allow a higher engraftment of intravenously injected human hematopoietic cells than SCID mice, 8, 9 as hosts for human fetal bone fragments (hu-NOD-SCID mice). A murine bone marrow stromal cell line, MS5, 10 that supports human hematopoiesis, 11 was engineered by gene transfer to produce human interleukin-3 (hu-IL3-MS5), a cytokine which stimulates the proliferation of human hematopoietic progenitors in vitro, but does not cross-react with mouse cells. Support of human hematopoiesis by hu-IL3-MS5 and MS5 cells was evaluated in coculture experiments with human CD34 + cells. The transfected cells allowed higher proliferation and production of clonogenic precursors by CD34 + cells, than did native MS5 cells.
When injected intravenously into hu-NOD-SCID mice, hu-IL3-producing MS5 cells seeded the bone marrow and several other organs in host mice, as well as the engrafted human bone marrow. hu-IL3 was detected in the mouse serum for up to 8 weeks, and the implantation of hu-IL3-MS5 cells in hu-NOD-SCID mice significantlly stimulated human hematopoiesis in the transplanted bones.
Materials and methods

hu-IL3-MS5 cells
We used the pCEP4 plasmid (Invitrogen, Leek, The Netherlands), a mammalian expression vector which uses the CMV enhancer/promoter for the transcription of recombinant genes. 12 The coding sequence from human IL3 (R&D Systems, Minneapolis, MN, USA) was ligated to synthetic fragments containing the natural leader sequence of human IL3 and subcloned into the pCEP4 plasmid. The resulting plasmid was named pIL3. 10 6 MS5 cells in exponential growth were subjected to electroporation (500 V, 1070 F, gene-pulser II apparatus, BioRad, Hercules, CA, USA) in the presence of 200 g of pIL3 vector in RPMI medium (Gibco, Grand Island, NY, USA). In order to stably establish hu-IL3-MS5 sublines, transfected MS5 cells were selected using 400 g hygromycin (Boehringer Mannheim, Mannheim, Germany) per ml of IMDM (Gibco) supplemented with 10% fetal calf serum (FCS) (Gibco), 10% horse serum (HS) (Sigma, St Louis, MO, USA) and 1% bovine serum albumin (BSA) (Sigma). After 3 weeks of selection, cells were expanded in the same medium without hygromycin. The production of hu-IL3 was determined with an enzyme-linked immunosorbent assay (ELISA) kit (human IL3-HS-cytokine immunoassay, R&D Systems) in a 1-week culture supernatant of confluent cells.
Coculture of hu-IL3-MS5 and CD34
+ cells CD34 + cells were positively selected from cord blood using Ceprate immunoaffinity columns (CellPro, Bothell, WA, USA) as previously described. 13 24-well plates (Falcon, Becton Dickinson, NJ, USA) were precoated with 1% gelatin at 37°C, in 5% CO 2 in air. Wells were then rinsed twice with PBS. 3 × 10 4 MS5 or hu-IL3-MS5 cells were seeded into 0.5 ml in each well. 24 h later 10 4 CD34 + cells suspended in 0.5 ml were added to each well as previously described.
14 Nonadherent hematopoietic cells were harvested at intervals, counted and examined under the microscope after staining using a modified Wright-Giemsa method (Diff-Quick; Baxter, Maurepas, France). Assays for hematopoietic progenitors were performed by slight modification of an established method. 15 Briefly, hematopoietic cells from cocultures were plated in triplicate in 35-mm dishes (Becton Dickinson, San Jose, CA, USA) at 10 3 cells/ml in methylcellulose medium with recombinant cytokines (MethoCult TMGF+ H4435; StemCell Technologies, Vancouver, Canada). Cultures were incubated at 37°C in humidified 5% CO 2 in air and removed from the incubator after 14 days. Colonies were defined as greater than 40-cell aggregates and counted using an inverted microscope.
hu-NOD-SCID mice
Human fetal tissues (20 to 24 weeks of gestation) were obtained from therapeutic abortions. Bone fragments were implanted into the subcutaneous region of the flanks of 6-8-week-old male NOD-SCID mice anesthetized with Hypnomidate (Laboratoire Janssen, Boulogne-Billancourt, France). For each experiment a series of mice (one to four) engrafted with bone marrow pieces from the same donor, was used. A total of 16 mice corresponding to five donors was used in this study. 5 × 10 6 hu-IL3-MS5 cells were injected through the retro-orbital plexus from 0 to 6 weeks after human bone transplantation. A second infusion of 5 × 10 6 cells was performed 1 week later in some experiments. Control mice were injected with non-transfected cells or with PBS. 100 to 200 l of blood were collected each week for up to 2 months. Presence of hu-IL3 in mouse serum was tested and blood cell pellets were kept frozen for PCR analysis. Due to the fragility and size of the animals, larger volumes were not collected. According to the manufacturer, the minimal sample volume for testing hu-IL3 was 100 l. The low levels observed in the first experiments led us not to dilute the collected serum. It was therefore not possible to duplicate dosages. Mice were killed by cervical dislocation from 1 week to 2 months after stromal cell injection. Human bone marrow cells were recovered from human bone grafts after incubation in collagenase-dispase 0.5 mg/ml (Boehringer Mannheim) for 15 min at 37°C. Murine bone marrow cells were flushed from the tibiae and femurs. Cell suspensions were immunostained to characterize human hematopoietic cells, and subjected to PCR analysis. Fragments of liver, spleen, kidney, adrenal gland, lung and muscle were collected for PCR analysis.
RT-PCR and PCR analysis
Total cellular RNA was extracted from transfected cells as previously described, 16 incubated 30 min in the presence of DNAse (Gibco), heated at 90°C for 5 min and promptly cooled at 4°C. The RT-PCR was carried out as previously described. 17 Briefly, total cellular RNA was first annealed with 1 mm of oligo-dT15 (Sigma) and then incubated at 42°C for 1 h in the presence of 100 units Moloney murine leukemia virus reverse transcriptase (Gibco). Reverse transcriptase reaction mixtures were then subjected to PCR amplification. Specificity of RT-PCR results was checked by direct amplification of RNA without the reverse transcription step.
DNA isolated from tissue samples or pelleted cells was subjected to PCR amplification using a sense primer (GTGGTTTGTCCAAACTCATC) and an anti-sense primer (AGAGCTCGTTTAGTGAACCG) localized on both sides of the IL3 gene (inside the multiple cloning site of pCEP4). Nested PCR was performed using sense (CCAAACTCAATGTATCTTATCATGTCT) and anti-sense (TCAGATCTCTAGAAGCTGGGT) primers localized in the multiple cloning site of pCEP4. These pairs of primers allow the detection of a 542 bp fragment, as visualized with ethidium bromide on a 2% agarose gel. As an internal control, a 590 bp region of the endogenous mouse RAP-SYN gene 18 was also amplified using a second set of unique 30 bp primers (sense: AGGACTGGGTGGCTTCCAACTCCCAGACAC, antisense: AGCTTCTCATTGCTGCGCGCCAGGTTCAGG) which allow the detection of a 590 bp fragment.
Mouse bone marrow culture
Mouse bone marrow cells from hu-NOD-SCID mice were flushed and cultured like MS5 cells in DMEM, 10% FCS, 10% HS. Adherent cells were then subjected to hygromycin selection (400 g/ml) in order to isolate hu-IL3-MS5 cells. The production of hu-IL3 was assayed in the culture supernatant by ELISA (human IL3-HS-cytokine immunoassay, R&D Systems).
Human hematopoiesis
Cells from the human bone graft and murine bone marrow were immunostained with anti-human monoclonal antibodies conjugated with either fluorescein isothiocyanate (FITC) or phycoerythrin (PE). The antibodies used were: anti-CD45 (T29/33), -CD33 (VM-54), -CD19 (HD37), -CD34 (Birma K3), and isotype-matched control antibodies (DAKO, Glostrup, Denmark). Acquisitions were performed on a FACScan flow cytometer (Becton Dickinson) and analyzed with the CellQuest program (Becton Dickinson). Dead cells were excluded from the analysis using 7-aminoactinomycin D staining (Sigma) and analyses were performed on 7000 viable cells.
Results
Preparation and characterization of MS5 cells producing human IL3
MS5 cells were transfected by electroporation with a plasmid containing the human IL3 and hygromycin resistance genes, and stably transfected hu-IL3-MS5 cells were selected using hygromycin. The presence and transcription of the transgene were controlled in selected cells using PCR and RT-PCR (Figure 1 ). The expected 542 bp band of the PCR product was observed in hu-IL3-MS5 cell extracts. With respect to IL3 transgene expression, a similar observation was made using RT-PCR. Secretion of the hu-IL3 transgene product in selected cells was demonstrated by detection of human IL3 in cell culture supernatant. Stable hu-IL3 production was measured in culture supernatant of hu-IL3-MS5 cells (1-2 ng/week/10 6 cells) over a 6-month period. Hu-IL3 was not detectable in control MS5 cell supernatant (Ͻ0.5 pg/ml).
Hu-IL3-MS5 cells support human hematopoiesis in vitro
We analyzed the capacity of hu-IL3-MS5 cells, as compared to MS5 control cells, to support the growth of human progenitors and act on progenitor cell survival and differentiation in a long-term coculture system. CD34
+ cord blood cells were selected with 70-90% purity and seeded onto MS5 and hu-IL3-MS5 stromal layers. As shown in Figure 2a , a high level (up to 315 pg/ml) of human IL3 was detected in the supernatant of hu-IL3-MS5 cocultures for 45 days (undetectable in control). Hematopoietic cell numbers and CFU-GM present in the cultures were counted weekly and demonstrated a significant increase of the proliferation of hematopoietic cells (Figure 2b ) and the production of CFU-GM (Figure 2c ) in hu-IL3-MS5 cocultures as compared to MS5 controls. Table 1 shows differential counts of the human hematopoietic cell types which appeared in the culture medium when human CD34 + cells were cocultured with hu-IL3-MS5 or MS5 stromal layers. The proportion of differentiated cells (eosinophils, neu-
Figure 1
Detection of the pIL3 plasmid and its expression in hu-IL3-MS5 cells. MS5 cells were transfected with 200 g pIL3, selected during 3 weeks in 400 g/ml hygromycin, then amplified for 2 months. A 542-bp PCR product shows the presence of the pIL3 plasmid (PCR) and its expression (RT-PCR). Controls were as follows: Pos, IL3-encoding plasmid DNA; Neg, no DNA; No RT, no reverse transcription step. Hu-IL3 production in hu-NOD-SCID mice 5 × 10 6 hu-IL3-MS5 cells were injected intravenously into hu-NOD-SCID mice simultaneously with or after human bone engraftment. Blood from eight mice was collected weekly and hu-IL3 production was determined by ELISA. Figure 3 illustrates an experiment in which the level of hu-IL3 production in the first week was high (around 100 pg/ml). In the next 3 weeks the level of hu-IL3 decreased, then stabilized from week 5 to week 8 (around 12 pg/ml). When hu-IL3 production in the first week was lower (around 20 pg/ml), hu-IL3 was beyond threshold levels (Ͻ0.5 pg/ml) 3 weeks after infusion of the stromal cells. In control mice infused with MS5 cells or PBS, production of hu-IL3 was not detected. This indicates that the production of hu-IL3 did not originate from the human bone graft but from the implanted hu-IL3-MS5 cells.
Implantation of MS5 cells in hu-NOD-SCID mice
In order to identify the site(s) of implantation of hu-IL3-MS5 cells in the treated mice, PCR analysis was performed on sev-
Figure 3
Production of hu-IL3 in host mouse serum. Three mice bearing human bone graft from the same donor were studied. hu-IL3-MS5 cells were injected intravenously in hu-NOD-SCID mice, and serum was collected weekly thereafter. hu-IL3 production was assayed by ELISA. Control mice were infused with MS5 cells or PBS.
eral of their organs, as well as on the human grafts. Table 2 presents PCR analysis performed on tissues from mice which received hu-IL3-MS5 cells. hu-IL3-MS5 cells were detected in mouse bone marrow in all experiments and, in addition in the spleen, liver and lung in 5/7, 3/7 and 3/5 mice, respectively. Most interestingly, hu-IL3-MS5 cells were detected in the human bone grafts in 3/7 mice. Figure 4 shows analysis of the PCR products from experiments in which the transgene was detected in the bone marrow, spleen, liver, lung and in the human bone grafts, but not in the kidney, adrenal glands, muscle and blood of host mice. This series comprises three mice, two of them received hu-IL3-MS5 cells and one received MS5 cells.
hu-IL3-MS5 cells were detected in the bone marrow of all tested mice. In order to confirm the origin in the implanted cells of the detected hu-IL3, host bone marrow cells were cultured in the presence of hygromycin. After selection of a hygromycin-resistant subpopulation hu-IL3 could be evidenced in 3/3 experiments performed. After amplification, hu-IL3 was detected in the culture supernatant, attesting that the implanted hu-IL3-MS5 cells were functional (data not shown).
Effects of hu-IL3 production on human hematopoiesis in bone grafts
The presence of human hematopoietic cells in the human and host mouse bone marrow was evaluated by flow cytometry following immunostaining with antibodies against human antigens. Figure 5 shows the analysis of human hematopoietic cells in bone grafts from two different experiments. A significant stimulation of human hematopoiesis was observed in all sets of experiments where the hu-IL3-MS5 cells were detected in the human bone graft. In the experiment presented in Figure  5a , a five-fold increase in human hematopoiesis was observed in the bone graft of a mouse infused with hu-IL3-MS5 cells, as compared with mice infused with MS5 cells or PBS (45, 5 and 10% CD45 + cells in the bone graft, respectively). In the experiment presented in Figure 5b 
Discussion
Normal, malignant and transgenic human hematopoietic cells are now routinely grown in immunodeficient mice where their development can be supported either by the blood-forming tissues of the mouse host itself, or by surgically implanted human hematopoietic organs. Yet, none of these surrogate assay systems can fully reproduce human blood cell homeostasis. Human bone marrow cells require added human growth factors to develop in the bone marrow and spleen of SCID or NOD-SCID mice and transplanted intact fetal bone marrow cannot support erythropoiesis in the absence of human erythropoietin administered independently. The overall level of human hematopoiesis achieved is still highly variable. It is therefore likely that stem cell/stroma interactions are 
mBM, murine bone marrow; Lv, liver; Sp, spleen; Lu, lung; Ky, kidney; AG, adrenal gland; Ms, muscle; hBM, human bone marrow; ND, not determined.
Figure 4
Detection of the pIL3 plasmid in DNA isolated from hu-NOD-SCID mouse tissues. DNA was extracted from murine bone marrow (mBM), liver (Lv), spleen (Sp), lung (Lu), kidney (Ky), adrenal gland (AG) and muscle (Ms) and from human bone grafts (hBM). PCR amplification was performed. A 542-bp product shows the presence of the pIL3 plasmid and a 590 bp product is an internal control for mouse DNA (RAP-SYN gene) presence. The analysis of PCR products from one set of experiments is presented. not optimally reproduced in mouse/human chimeras. Recent data suggest that intravenous infusion of very high numbers of human bone marrow cells into NOD-SCID mice may diminish the recruitment of human growth factors, 19 possibly because significant numbers of human stromal cells also get engrafted in these conditions. Several approaches have been previously developed in order to efficiently deliver growth factors to mice bearing human hematopoietic tissues and cells. The cotransplantation of human bone marrow stromal cells secreting hu-IL3 and human CD34
+ cells in bnx mice allowed
Figure 5
Effect of hu-IL3-MS5 cell presence on human hematopoiesis in human bone grafts from hu-NOD-SCID mice. Stromal cells were injected intravenously after human bone implantation. Bone graft cells were collected after collagenase-dispase treatment and immunostained with PE-or FITC-conjugated antibodies. Dead cells were excluded from the analysis. The data present the percentages of cells stained by each antibody in two sets of experiments. a higher level of hematopoietic cell engraftment than cotransplantation with native stromal cells. 20 Alternatively, rat fibroblasts were engineered to produce hu-IL3, included in matrigel and implanted subcutaneously into SCID mice 21 to which human CD34 + cells selected from mobilized peripheral blood cells were injected. Human hematopoiesis developed essentially in the cotransplant which produced hu-IL3. A third type of approach is the construction of mice transgenic for human growth factors. SCID mice transgenic for human GM-CSF and human IL3 displayed detectable levels of serum hu-GM-CSF, but no hu-IL3. 22 These mice supported the implantation of hu-GM-CSF-dependent leukemic cells, confirming the biological efficiency in vivo of the GM-CSF produced. The implantation of normal human hematopoietic cells remains to be studied in such mice. SCID mice transgenic for hu-GM-CSF, hu-IL3 and stem cell factor were also generated; 23 these mice permitted a higher level of engraftment of human hematopoietic cells in their bone marrow than non-transgenic SCID littermates, but this level remained lower than in normal NOD-SCID mice.
In this study we have used the NOD-SCID mouse as recipient for human fetal bone marrow. The murine stromal cell line MS5 engineered to produce hu-IL3 and injected intravenously into hu-NOD-SCID mice seeded the bone marrow, spleen, liver and lungs of the mice but also human bone grafts. The hu-IL3-MS5 cells preferentially engrafted their tissue of origin, the bone marrow, but also other organs and, most interestingly, human bone marrow. Hu-IL3-MS5 cells demonstrated higher efficiency in the support of human hematopoiesis in vitro than regular MS5 cells, and their implantation into hu-NOD-SCID mice was accompanied by a stimulation of human hematopoiesis in the bone grafts, as compared with mice infused with MS5 cells.
The origin of bone marrow stromal cells in patients who received bone marrow transplantation gave rise to several controversial studies. Some identified a participation of donor stromal cells in the host stroma, 24, 25 while other studies identified only stromal cells of host origin. 26, 27 Several investigations were performed in animals to evaluate the ability of bone marrow stromal cells to seed the bone marrow. CFU-F of donor origin were detected in the bone marrow of irradiated mice after bone marrow transplantation. 28 Engraftment of a clonal murine bone marrow stromal cell line in irradiated mice has been described, which stimulated hematopoietic recovery after total body irradiation. 29 Donor stromal cells were detected only in the bone marrow of recipients but other studies indicate an ability for bone marrow stromal cells to engraft other tissues as well. Expanded cultured adherent cells from the bone marrow of transgenic mice expressing a minigene for human collagen I were injected into irradiated mice and later detected in several tissues: marrow, spleen, bone, lung and cartilage. 30 These data and observations pertaining to the ability of marrow stromal cells to differentiate in vitro into osteoblasts, chondrocytes, adipocytes and myoblasts led these authors to propose marrow stromal cells as stem cells for non-hematopoietic tissues and envisage their use for gene therapy. 31 For these authors, the irradiation which was necessary to achieve stromal cell implantation in the host mice constituted a limiting parameter for the application of such a therapy. In our experiments, stromal cells were injected once or twice by the intravenous route without irradiation of the mice, and they seeded the mouse bone marrow as well as human bone grafts which indicates that there are no barriers to the engraftment of stromal cells other than immunosuppression. These authors also suggest that engraftment of stromal cells in various organs is related to the duration of experiments. Donor cells were not detected during the first week after cell infusion. At 1 month, donor cells accounted for 2 to 12% of cells in mice tissues, and at 5 months the percentages of donor cells decreased (1 to 6%). Our results seem to be in agreement with this statement as we detected hu-IL3-MS5 cells in a larger number of organs when PCR analyses were performed 5 weeks or more after injection of stromal cells (PR175, PR156) when compared to shorter duration of experiment.
The choice of hu-IL3 as a cytokine to evaluate the effect of a growth factor produced in situ in the hu-NOD-SCID mouse was determined by the fact that IL3 is species-restricted. 32 Therefore mouse hematopoiesis is not modified by the production of hu-IL3, and mouse-IL3 does not interfere with human hematopoiesis. The second reason for this choice was that hu-IL3 stimulates the proliferation of all categories of hematopoietic precursors, leading to an overall amplification of hematopoiesis. The properties of hu-IL3-MS5 cells were evaluated in vitro and compared to those of MS5 cells. We observed that hu-IL3-MS5 cells possess an increased capacity to sustain the proliferation and differentiation of hematopoietic precursors in vitro as compared to MS5 cells. hu-IL3-MS5 cells implanted in mice produced a detectable quantity of hu-IL3. Human IL3 serum levels seemed to be higher in experiments in which hu-IL3-MS5 cells engrafted a large number of organs. The relationship between the number of cells per organ and the concentration of hu-IL3 in serum could not be established because the PCR performed was not quantitative. Qualitative PCR was used in order to favor the sensitivity of the technique since the expected proportion of target cells in the tissues was low. Figure 3 shows that hu-IL3 serum level increased after the second injection of stromal cells, then decreased and stabilized from 5 to 8 weeks. The constant level of hu-IL3 detected during this late period may have been produced by hu-IL3-MS5 cells stably implanted in the mouse. Each series of mice received bone fragments from a different donor. Therefore, hu-IL3 serum levels observed in the different series are difficult to compare on a statistical basis. The level of serum hu-IL3 was still low compared with the concentrations commonly used in in vitro assays but a significant stimulation of human hematopoiesis was observed in human bone grafts, yet only in cases when hu-IL3-MS5 cells were detected in these grafts. These data suggest that stimulation of hematopoiesis was due to the local production of hu-IL3. However, the serum levels of hu-IL3 seemed to be higher in those experiments compared to those observed when transfected cells were not detected in human bone implants. The respective effects of local and exogenous production of hu-IL3 could not be discriminated.
Importantly, infusion of IL3-producing stromal cells could even rescue hematopoiesis in bone transplant series in which, according to untreated graft analysis, less than 1% human hematopoietic cells were still present (Figure 5b ), reflecting a graft failure which is occasionally observed in this model. This may be of relevance to the therapeutic use of stromal cell transplantation in the treatment of drug-or radiation-induced bone marrow aplasia, for example. Clinical studies indicate that bone marrow-derived stromal progenitor cells can be intravenously infused without toxicity. 33 In conclusion, the implantation of transgenic bone marrow stromal cells described herein could be a relatively simple method to improve mouse chimera models of human bone marrow hematopoiesis. More basically, this setting could also be used to model the bone marrow homing of intravenously injected stromal cells or stromal cell precursors. The same experimental principle could probably also be applied to malignant human bone marrow hematopoiesis, which is also maintained during prolonged periods of time in its intact microenvironment implanted in SCID mice. 34 In that situation, provided that homing of the engineered cells to the diseased tissue(s) can be mastered, the possibility to locally deliver negative regulators of tumor growth through stromal cells could be explored.
